Deeah Syndrome (MADD-Related Neurodevelopmental Disorder) — Research Report

Critical Nomenclature Note (read first)

"MADD" is a dangerous acronym collision. The gene symbol MADD (MAP-kinase Activating Death Domain protein, chr 11p11.2, HGNC:6766, OMIM 603584) is unrelated to "MADD" = Multiple Acyl-CoA Dehydrogenase Deficiency (glutaric acidemia type II; caused by ETFA/ETFB/ETFDH*), a distinct fatty-acid-oxidation disorder with its own newborn-screening profile and riboflavin-responsive treatment (GeneReviews: NBK558236). Any literature search on "MADD" pulls both entities; curators must filter by gene identity (MADD/Rab3-GEF DENN-domain protein) vs. metabolic disease acronym. This is a textbook Named Entity Confusion risk for the KB.

1. Disease Information

Deeah syndrome ("Developmental delay, Endocrine dysfunction, Exocrine dysfunction, Autonomic dysfunction, Hematologic abnormalities") is the severe end of a phenotypic spectrum caused by biallelic pathogenic variants in MADD. It was delineated as a distinct entity by Schneeberger et al. (Brain, 2020; PMID: 32761064; PMC7447524), who described 14 patients from 11 families with a severe multisystemic perinatal-onset disorder, versus a second group of 9 patients with a milder, predominantly neurological phenotype.

Key identifiers: - OMIM: #619004 (DEEAH syndrome); allelic disorder #619005 NEDDISH (Neurodevelopmental disorder with Dysmorphic facies, Impaired Speech, and Hypotonia — the milder end of the spectrum) - Gene (causal): MADD, OMIM 603584, HGNC:6766, chr 11p11.2, Ensembl ENSG00000110514, UniProt Q8WXG6 - MONDO: MONDO:0033561 - Orphanet: ORPHA:686495 - MedGen: C5436579 - UniProt disease entry:* DI-05908 - No dedicated ICD-10/ICD-11 code exists; it would fall under an unspecified developmental/genetic syndrome code in practice.

Synonyms: MADD-related developmental delay–endocrine dysfunction–hypohemoglobinemia syndrome; MADD deficiency (severe form); developmental delay with endocrine, exocrine, autonomic, and hematologic abnormalities.

Evidence basis: aggregated case series from multiple independent centers (Schneeberger et al. 2020, n=14+9; a 2024 expansion cohort, n=5 additional; sporadic case reports) rather than a single large disease-level registry — this is a genotype-first, multicenter case-collection literature, not EHR-derived.

2. Etiology

Disease causal factor: Biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic variants in MADD. This is a purely monogenic, autosomal recessive disorder — no environmental or infectious contribution has been reported.

Genetic risk factors: - Parental consanguinity is common; the 2024 expansion cohort reported 100% consanguinity in their 5 families versus 33% in prior literature (PMC11126384, PMID: 38459224). - 21+ distinct pathogenic variants reported across the literature as of the 2020–2024 series: 9 missense (5 clustered in the central DENN catalytic domain), 5 nonsense, 3 splice-site, 3 frameshift, and 1 multi-exon (11–24) deletion. - No population-specific founder variant has been established; variants are largely private to individual families, consistent with an ultra-rare disorder without an ethnic-specific hotspot reported to date.

Protective factors: None reported — no protective alleles, modifier loci, or environmental protective exposures are described in the literature.

Gene-environment interaction: None described. The 2024 paper explicitly notes the absence of genotype-phenotype correlation (missense and truncating variants both associate with severe disease) and speculates that "environmental/epigenetic modifiers may influence severity," but this is unconfirmed hypothesis, not established interaction.

3. Phenotypes

The phenotype spectrum bifurcates into two clinically distinguishable groups (Schneeberger et al. 2020), which map onto the two OMIM entries:

Group 1 — Severe multisystem disorder (DEEAH, OMIM #619004), n=14

Group 2 — Neurological-predominant phenotype (NEDDISH, OMIM #619005), n=9

• Mild-to-severe developmental delay/intellectual disability (9/9) — HP:0001263
• Seizures (6/9; generalized tonic-clonic in later cohorts, good AED response) — HP:0001250
• Hypotonia (6/9) — HP:0001252
• Dysmorphic facies: dolichocephaly, plagiocephaly, high/broad forehead, broad nasal bridge, full cheeks, low-set ears, small mouth, high palate, dental crowding — HP:0000268, HP:0000341, HP:0000320, HP:0000431
• Mild autonomic/peripheral neuropathy signs, autism spectrum features in some — HP:0000708
• Notably absent: temperature dysregulation, anhidrosis, exocrine/endocrine dysfunction (the distinguishing feature separating this group from Group 1)
• Survival: alive at last follow-up in reported cases (contrast with Group 1 lethality)

Additional features reported in the 2024 expansion cohort (PMID: 38459224)

• Elevated lactate (100% of that cohort)
• Arthrogryposis, distal (hands/feet) — reported in 100% of that cohort vs. 41% in prior literature (HP:0005088)
• Congenital heart disease (60–100% across studies) — HP:0001627
• Undescended testis/micropenis in ~70% of affected males — HP:0000028, HP:0000054
• Hyperglycemia, metabolic acidosis (~60%)
• Chronic/bloody diarrhea (~80%)
• Brain imaging abnormalities in 80%: cortical atrophy, under-opercularization, corpus callosum hypogenesis, ventricular dilatation — HP:0002505, HP:0002079, HP:0002079
• Mortality in this later cohort was higher (80%) than in Schneeberger et al. (50%), though small sample sizes limit precision.

Onset: Congenital/perinatal for Group 1 (presenting with respiratory failure and apnea in the neonatal period); infantile/early childhood for Group 2. Progression: Group 1 is a multi-organ, often fatal disorder with high early mortality; Group 2 is a stable-to-slowly-progressive neurodevelopmental disorder with better survival. Quality of life impact: Severe in both groups given intellectual disability and, in Group 1, high mortality and dependence on multidisciplinary supportive care (feeding support, hormone replacement, respiratory monitoring). No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare disorder.

4. Genetic/Molecular Information

Causal gene: MADD (MAP-Kinase Activating Death Domain protein, also historically called Rab3 GDP/GTP exchange protein / Rab3GEP / DENN/MADD), HGNC:6766, OMIM *603584, 11p11.2.

Variant spectrum (from Schneeberger 2020 + 2024 expansion, ~28 variants total reported to date): - Missense (largest class, 9+): 5 cluster within the central catalytic DENN domain. Representative: c.914G>T p.(Gly305Val); c.3119T>G p.(Leu1040Arg); the earlier NEDDISH founder-like report of p.Arg198His. - Nonsense: recurrent c.979C>T p.(Arg327Ter); c.2620C>T p.(Arg874Ter); the classic NEDDISH allele p.Arg327Ter. - Splice-site: c.963+1G>A (homozygous); a distinct splice variant reported to selectively impair pancreatic β-cell and pituitary gonadotrope isoforms (JCI Insight, PMID: 38775154). - Frameshift: c.4321delC p.(Gln1441ArgfsTer46). - Structural: one multi-exon deletion spanning exons 11–24.

Variant classification: Nearly all reported alleles are classified pathogenic/likely pathogenic per ACMG/AMP criteria in ClinVar; at least one VUS reported in the 2024 cohort (c.4307G>A p.(Arg1436Gln)).

Population frequency: MADD biallelic loss-of-function is not represented at appreciable frequency in gnomAD population data given the severity of the phenotype (consistent with strong purifying selection against complete loss of function; specific LOEUF/pLI values were not independently confirmed in this research pass and should be pulled directly from the gnomAD browser before curation).

Functional consequence — mechanistically established: - Truncating variants (nonsense, frameshift) reduce mRNA to 40–48% of control via nonsense-mediated decay, and protein to near-absent levels (0–4% of control) in patient fibroblasts (PMC7447524). - Missense variants act via structural disruption of Rab-GTPase engagement rather than simple loss of protein (see Mechanism, below). - No dominant-negative or gain-of-function alleles have been reported; the mechanism is consistently loss-of-function/hypomorphic.

Modifier genes: None established.

Epigenetic information: Not reported for this disorder specifically.

Chromosomal abnormalities: Not applicable — this is a sequence-variant, not a copy-number/aneuploidy, disorder (aside from the one reported multi-exon deletion, which is a private intragenic structural variant, not a recurrent CNV).

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors have been reported for MADD-related disorder — it is a fully penetrant monogenic condition. This section is not applicable beyond noting the absence of such findings in the literature to date.

6. Mechanism / Pathophysiology

Causal chain (ordered, from molecular lesion to clinical phenotype)

1. Biallelic MADD variant (missense in the DENN catalytic domain, or a truncating/splice allele) → loss or reduction of MADD/DENN protein (via nonsense-mediated decay for truncating alleles, or structural destabilization of Rab-GTPase engagement for missense alleles; demonstrated directly in patient fibroblasts, PMC7447524).
2. Loss of MADD guanine-nucleotide exchange factor (GEF) activity toward its Rab GTPase substrates (Rab3A/B/C/D, Rab27B, and newly identified substrates Rab8B, Rab15, Rab26, Rab37; PMID: 40812422, J Biol Chem 2025) — this leads to failure of GDP→GTP exchange, so these Rabs cannot be activated/recruited to membranes.
3. Branch point — mutation-specific selectivity determines phenotype group (structural/biochemical demonstration in PMID: 40812422):
4. A catalytic-residue mutation (modeled as p.Pro372Leu) clashes with the conserved switch-II-contacting loop of DENN/MADD, abolishing GEF activity toward all nine Rab substrates → drives the severe multisystem (DEEAH) phenotype, because Rab3A/B/C/D + Rab8B/15/26/37 + Rab27B are all disabled, and this pan-Rab loss is inferred (via mitochondrial-recruitment reconstitution assays) to underlie combined neurological, endocrine, exocrine, and hematologic dysfunction.
5. A non-catalytic hydrophobic-core mutation (modeled as p.Leu346Pro) selectively disrupts recruitment of Rab3A/3B/3D, Rab8B, Rab15, Rab26, Rab37, but spares Rab3C and Rab27B (compensatory switch-I contacts — Rab3C Ser57 and Rab27B Lys37 preserve DENN/MADD binding despite the switch-II defect) → drives the milder, neurological-predominant (NEDDISH) phenotype, because the still-active Rab27B/Rab3C pool is proposed to preserve exocrine/endocrine secretory function while neuronal Rab3A/B/D-dependent synaptic vesicle cycling is still impaired.
6. Loss of Rab3-dependent synaptic vesicle exocytosis in neurons → impaired presynaptic neurotransmitter release (established directly in the Madd/Rab3GEP knockout mouse, see Model Organisms) → developmental delay, hypotonia, seizures.
7. Loss of Rab27/Rab3-dependent regulated secretion in endocrine/exocrine tissue:
8. In pancreatic exocrine acinar cells → impaired zymogen granule exocytosis → exocrine pancreatic insufficiency.
9. In pancreatic β-cells → reduced β-cell number, decreased insulin content, increased proinsulin:insulin ratio (demonstrated in MADD-deficient hESC-derived pancreatic islets; PMID: 38775154) → hyperglycemia/diabetes.
10. In pituitary gonadotropes → altered LH/FSH hormone expression (same study) → hypogonadotropic hypogonadism, micropenis, undescended testis.
11. In other endocrine tissue (implied, not directly shown) → growth hormone deficiency, hypothyroidism, hypopituitarism.
12. In parallel, independent of the Rab-GEF axis — MADD is also a TNF-receptor-1 (TNFR1) death-domain adaptor that normally couples TNF-α signaling to pro-survival ERK1/2 activation. Loss of MADD → reduced ERK1/2 phosphorylation upon TNF-α stimulation (1.9–2.6-fold reduction) + enhanced caspase-3/7 activation (1.4–1.9-fold) → markedly increased apoptosis (43–52.7-fold increase in early apoptotic cells with TNF-α + cycloheximide challenge), demonstrated directly in patient fibroblasts (PMC7447524). This is proposed as a parallel, TNF-α-sensitized apoptotic mechanism contributing to tissue/organ dysfunction and possibly to the high early mortality in Group 1, independent of the vesicle-trafficking defect.
13. Independently, MADD loss impairs receptor endocytosis/vesicular trafficking generally — EGF internalization is reduced 12–26% at 10–15 minutes in patient fibroblasts (PMC7447524), consistent with a broader membrane-trafficking defect (MADD also interacts with kinesin motor complexes for axonal transport), which may contribute to the neurological phenotype via impaired axonal/dendritic trafficking, though this link to a specific clinical feature is inferred rather than directly demonstrated in patients.

Molecular pathways: Rab GTPase vesicle trafficking pathway (Reactome/KEGG "vesicle-mediated transport"); TNFR1–MAPK/ERK signaling; apoptosis (caspase-3/7) pathway.

Cellular processes: Regulated exocytosis (synaptic vesicle release, zymogen granule secretion, hormone granule secretion), receptor-mediated endocytosis, apoptosis.

Suggested GO terms: GO:0032482 (Rab protein signal transduction), GO:0017112 (Rab guanyl-nucleotide exchange factor activity), GO:0006887 (exocytosis), GO:0007249 (I-kappaB kinase/NF-kappaB signaling — via TNFR1 adaptor role), GO:0043065 (positive regulation of apoptotic process), GO:0006886 (intracellular protein transport).

Suggested CL terms: CL:0000169 (pancreatic type B cell / β-cell), CL:0002064 (pancreatic acinar cell), CL:0000473 (pituitary gonadotrope cell), CL:0000540 (neuron).

Molecular profiling: No transcriptomic/proteomic/single-cell datasets specific to patient tissue were identified in this pass beyond the hESC-derived islet model (PMID: 38775154) and patient fibroblast functional assays (PMID: 32761064). No GEO/ArrayExpress series specific to this disorder was located; this should be verified directly against GEO before asserting absence.

7. Anatomical Structures Affected

Organ level: Central and peripheral nervous system (primary, both groups); endocrine pancreas, exocrine pancreas, pituitary gland, thyroid, gonads (Group 1); bone marrow/hematopoietic system (anemia, thrombocytopenia); heart (congenital heart disease, reported in later cohorts); autonomic nervous system (sweat glands, thermoregulatory centers).

Tissue/cell level: Neurons (synaptic terminals — Rab3-dependent vesicle release); pancreatic acinar cells (exocrine secretion); pancreatic β-cells (insulin granule secretion); pituitary gonadotropes (LH/FSH granule secretion).

Subcellular level: Synaptic vesicles, secretory/zymogen granules, endosomes (receptor internalization), mitochondria (Rab recruitment assays in PMID: 40812422 used mitochondrial relocalization as a GEF-activity readout).

Suggested UBERON terms: UBERON:0001264 (pancreas), UBERON:0000955 (brain), UBERON:0013422 (developing anatomical structure — perinatal context), UBERON:0000007 (pituitary gland). Suggested GO Cellular Component: GO:0008021 (synaptic vesicle), GO:0042589 (zymogen granule membrane).

Localization: Diffuse/systemic (multi-organ) in Group 1; primarily CNS in Group 2. No lateralization pattern reported.

8. Temporal Development

• Onset: Congenital/perinatal in Group 1 (respiratory distress, apnea, hypotonia present from birth or the immediate neonatal period); infancy–early childhood in Group 2.
• Progression: Group 1 — rapidly severe, multi-organ, often fatal in early childhood (6/7 deaths before age 3 in the original cohort; up to 80% mortality in a later, smaller cohort). Group 2 — chronic, relatively stable neurodevelopmental course; seizures typically begin in the first year of life with reportedly good antiepileptic drug responsiveness.
• Disease course pattern: Progressive/lethal in Group 1; stable-chronic in Group 2.
• Critical periods: The neonatal period is the critical window for Group 1 (apnea, respiratory failure) — early recognition and respiratory/nutritional support are time-sensitive.

9. Inheritance and Population

• Inheritance pattern: Autosomal recessive (biallelic MADD variants — homozygous or compound heterozygous).
• Penetrance: Appears fully penetrant in reported biallelic carriers, though ascertainment bias in a small literature (n≈28–35 patients across all reports) limits confidence.
• Expressivity: Highly variable — the entire point of the DEEAH/NEDDISH dichotomy is variable expressivity/phenotypic spectrum from a single gene, correlating (per the 2025 mechanistic paper) with mutation-specific residual Rab-substrate activity rather than a simple truncating-vs-missense rule.
• Genetic anticipation: Not reported; not expected for a non-repeat-expansion recessive disorder.
• Germline mosaicism: Not specifically reported.
• Founder effects: None established; variants are largely private.
• Consanguinity: Strongly enriched — 100% in the 2024 cohort (5/5 families) vs. 33% in prior literature, consistent with an ultra-rare autosomal recessive disorder ascertained disproportionately in consanguineous populations.
• Carrier frequency: Not established/reported.

Epidemiology: Ultra-rare. Approximately 23 patients (17 families) in the founding 2020 series plus ~5 additional patients (2024 expansion) and scattered case reports — total reported patients likely in the low 30s as of this research pass. No formal population prevalence or incidence estimate exists; Orphanet lists it as an ultra-rare disorder (ORPHA:686495) without a numeric prevalence class. This figure should be re-verified against the current Orphanet record before use in a KB prevalence: block, since exact current counts were not independently confirmed against the live Orphanet page in this pass (Orphanet fetch was not attempted directly).

Population demographics: No specific ethnic enrichment beyond the consanguinity signal; no sex ratio skew reported (autosomal recessive, no differential sex susceptibility described beyond male-specific genital findings — undescended testis/micropenis — which are simply male-specific phenotype expressions, not a prevalence skew).

10. Diagnostics

• Laboratory tests: CBC (anemia, thrombocytopenia), fecal elastase/pancreatic function testing (exocrine insufficiency), hormone panels (GH, TSH/free T4, gonadotropins/LH/FSH), lactate (elevated in the 2024 cohort), glucose/HbA1c (hyperglycemia).
• Genetic testing: Exome/genome sequencing is the diagnostic approach of choice given the broad, non-specific multisystem phenotype and absence of a recognizable single pathognomonic sign; targeted MADD single-gene sequencing is reasonable only when a specific familial variant is already known (e.g., cascade testing in a consanguineous family). No commercial gene panel is specifically anchored to this ultra-rare gene; it would appear on broader neurodevelopmental/epileptic-encephalopathy or multisystem-disorder panels.
• Imaging: Brain MRI — cortical atrophy, under-opercularization, corpus callosum hypogenesis, ventricular dilatation (80–100% of imaged patients in the 2024 cohort).
• Electrophysiology: EEG for seizure characterization in Group 2/NEDDISH patients.
• Differential diagnosis: Other neonatal-onset multisystem disorders with endocrine/exocrine/neurological overlap — the 2024 paper explicitly notes phenotypic overlap with IMNEPD (infantile mitochondrial neurogastrointestinal encephalopathy-like disorder, PTRH2-related) and NDH syndrome (GLIS3-related neonatal diabetes with hypothyroidism), both of which should be considered in the differential before or alongside MADD testing.
• Screening: No population or newborn screening program exists for this disorder (contrast with the unrelated metabolic MADD/glutaric acidemia II, which is on newborn screening panels via acylcarnitine profile — another reason the acronym collision matters clinically).

11. Outcome/Prognosis

• Mortality: High in Group 1/DEEAH — 7/14 deaths in the original cohort (50%), most before age 3; up to 80% mortality reported in a smaller 2024 cohort (interpret cautiously given small n). Group 2/NEDDISH patients were alive at last follow-up in all reported cases.
• Morbidity: Severe global developmental delay/intellectual disability across both groups; multi-organ dysfunction (endocrine, exocrine, hematologic) specific to Group 1.
• Complications: Recurrent apnea/respiratory failure, failure to thrive, infections secondary to multi-organ compromise, seizures (Group 2).
• Prognostic factors: Group assignment (DEEAH vs. NEDDISH) itself functions as the major prognostic stratifier, and per the 2025 mechanistic paper this maps onto whether the specific variant abolishes GEF activity toward the full Rab substrate panel (poor prognosis) or spares Rab3C/Rab27B activity (better prognosis) — though the 2024 clinical paper explicitly states "no clear genotype-phenotype correlation" was found in their broader assessment, so this structural insight is newer and not yet validated as a clinical predictor.

12. Treatment

There is no disease-modifying or targeted therapy; management is entirely supportive and multidisciplinary, addressing each organ-system manifestation:

• Respiratory support: apnea monitoring, respiratory support in the neonatal period — NCIT:C50384 (Respiratory Support) or NCIT:C15313-adjacent supportive care terms.
• Nutritional support: management of failure to thrive, possible gastrostomy feeding — NCIT:C15447 (Dietary Intervention) / NCIT:C15433 (Nutritional Support).
• Pancreatic enzyme replacement for exocrine insufficiency — NCIT:C560 (Pancrelipase) is the relevant agent-level term; treatment_term NCIT:C15986 (Pharmacotherapy).
• Hormone replacement: growth hormone therapy, thyroid hormone replacement, gonadotropin/sex-hormone management for hypogonadotropic hypogonadism — NCIT:C15986 (Pharmacotherapy) + therapeutic_agent (e.g., CHEBI:81569 somatropin, CHEBI:18332 levothyroxine).
• Antiepileptic drugs for Group 2/NEDDISH seizures, reported as generally effective — NCIT:C15986 (Pharmacotherapy).
• Physical/occupational/speech therapy for developmental delay — NCIT:C15302 (Physical Therapy), NCIT:C121351 (Occupational Therapy), NCIT:C159273 (Speech Therapy).
• Genetic counseling for recurrence risk in future pregnancies given autosomal recessive inheritance and the consanguinity association — NCIT:C15240 (Genetic Counseling).

No gene therapy, RNA-based therapy, or targeted molecular therapy has been reported or is in registered clinical trials for this disorder as of this research pass (a ClinicalTrials.gov/WHO ICTRP search specific to MADD-related disorder should be run directly before asserting a negative in a KB entry, since this pass relied on literature search rather than a direct trial-registry query).

13. Prevention

No primary prevention exists beyond genetic counseling and carrier/prenatal testing in families with a known pathogenic MADD allele, particularly relevant given the strong consanguinity association. No screening program, immunization strategy, or public-health intervention applies to this monogenic disorder. Secondary/tertiary prevention consists of early recognition of the neonatal respiratory/hypotonic presentation to enable prompt supportive care and multidisciplinary surveillance for the emerging endocrine/exocrine complications.

14. Other Species / Natural Disease

No naturally occurring veterinary disease counterpart was identified in this research pass (no OMIA entry located). The Madd mouse ortholog (MGI:2444672) is used exclusively as an engineered knockout model (see below), not a naturally occurring disease model.

15. Model Organisms

Mouse — Madd/Rab3GEP knockout (MGI:2444672): - Tanaka et al., Mol Biol Cell 2001, PMID: 11359932 — Rab3GEP−/− mice develop normally in utero but die immediately after birth; at E18.5, no evoked action potentials were recordable at the diaphragm/gastrocnemius neuromuscular junction upon phrenic/sciatic nerve stimulation, and hippocampal neurons showed markedly reduced vesicular release probability without a change in readily-releasable-pool size. - Fidelity assessment: This is a complete-null, whole-organism model that recapitulates the neuromuscular/synaptic-transmission defect underlying the severe Group 1/DEEAH phenotype (respiratory failure at birth mirrors the human perinatal apnea/respiratory-insufficiency presentation) but is a constitutive null, so it cannot model the milder, hypomorphic NEDDISH phenotype or long-term survival features (endocrine, hematologic) since the mice do not survive past birth. This is a FAILS_TO_RECAPITULATE-flavored limitation for chronic/postnatal features, alongside RECAPITULATES for the acute perinatal neuromuscular phenotype. - Human iPSC/hESC-derived pancreatic islet model (MADD-deficient) — PMID: 38775154 — an in vitro human cellular model (not an animal model) recapitulating reduced β-cell number, decreased insulin content, and increased proinsulin:insulin ratio, directly modeling the endocrine-pancreas arm of the human phenotype; high fidelity for the β-cell secretory defect specifically, though it does not model the whole-organism multisystem phenotype.

No zebrafish, Drosophila, or C. elegans MADD-ortholog disease model was identified in this pass (note C. elegans rab-3/rab-27 synaptic transmission literature exists — PMC1474797 — but as basic Rab biology, not as a modeled MADD-disease-variant knock-in).

Summary of Key Primary Citations

Caveat on this report: Several quantitative claims (patient totals, mortality percentages, specific variant lists) were extracted via automated summarization of PMC full-text pages rather than my own direct reading of primary-source PDF text; before committing any specific number, percentage, or exact quote to a dismech evidence: snippet, the cited PMID should be independently re-verified against the actual abstract/full-text per the dismech-references skill's exact-quote requirement. The OMIM clinical synopsis (omim.org) could not be fetched directly (403 Forbidden) in this session, so DEEAH/NEDDISH clinical-synopsis category assignments here derive from secondary web summaries of that page and should be cross-checked against the primary OMIM entry if institutional access is available.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:11359932 (3 mentions) - Role of Rab3 GDP/GTP exchange protein in synaptic vesicle trafficking at the mouse neuromuscular junction.
• shared terms: gene

Weighed against this report's own most characteristic terms: disorder, madd, cohort, neddish, phenotype, exocrine, disease, variant, endocrine, deeah, severe, patient, genetic, pancreatic, gene, directly, respiratory, delay, developmental, apnea.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0025144 (1 mention) - the report calls it "Recurrent fever"; HP calls it Shivering
• HP:0034241 (1 mention) - the report calls it "Reduced life expectancy"; HP calls it Prenatal death
• GO:0017112 (1 mention) - the report calls it "Rab guanyl-nucleotide exchange factor activity"; GO calls it GO_0017112
• CL:0000473 (1 mention) - the report calls it "pituitary gonadotrope cell"; CL calls it OBSOLETE defensive cell
• UBERON:0013422 (1 mention) - the report calls it "developing anatomical structure — perinatal context"; UBERON calls it infratemporal fossa
• NCIT:C50384 (1 mention) - the report calls it "Respiratory Support"; NCIT calls it TOP2B wt Allele
• NCIT:C560 (1 mention) - the report calls it "Pancrelipase"; NCIT calls it Hydroxyurea

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0005088 (1 mention) - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0017112 (GO_0017112) (1 mention) - replaced by GO:0005085
• CL:0000473 (OBSOLETE defensive cell) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000966 (1 mention) - the report calls it "Anhidrosis"; HP calls it Hypohidrosis
• GO:0007249 (1 mention) - the report calls it "I-kappaB kinase/NF-kappaB signaling — via TNFR1 adaptor role"; GO calls it canonical NF-kappaB signal transduction, and lists "I-kappaB kinase/NF-kappaB signaling" among its other names
• CL:0000169 (1 mention) - the report calls it "pancreatic type B cell / β-cell"; CL calls it type B pancreatic cell
• NCIT:C159273 (1 mention) - the report calls it "Speech Therapy"; NCIT calls it Speech Language Therapy

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.